Early Onset Sepsis in Neonates: A Professional Guide to Risk Assessment and Management

Recent Trends in Early Onset Sepsis Management

Recent years have seen a shift away from universal empirical antibiotic therapy for newborns with suspected early onset sepsis (EOS). Neonatal care centers increasingly adopt multivariate risk assessment tools—such as the Kaiser Permanente sepsis calculator—to stratify infants based on maternal risk factors, clinical presentation, and laboratory values. This approach aims to reduce unnecessary antibiotic exposure while maintaining safety for the few infants who truly need treatment. Antibiotic stewardship programs have also gained traction, with many units implementing formal protocols to review and stop antibiotics within 48 hours if cultures remain negative.

Background and Pathophysiology

Early onset sepsis is defined as a systemic bacterial infection occurring within the first 72 hours of life, most commonly caused by Group B Streptococcus (Streptococcus agalactiae) and Escherichia coli. Transmission typically occurs vertically from mother to infant during labor or shortly after birth. Key risk factors include maternal intrapartum fever, prolonged rupture of membranes, chorioamnionitis, prematurity, and low birth weight. Intrapartum antibiotic prophylaxis has reduced GBS-related EOS incidence, but challenges remain in identifying at-risk infants who appear well at birth.

Key Concerns for Clinicians and Caregivers

• Overtreatment versus missed cases: Many well-appearing term infants receive antibiotics based on maternal risk factors alone, leading to unnecessary NICU admissions and disruption of breastfeeding. Conversely, a small number of infants with subtle signs may be discharged too soon.
• Antibiotic resistance: Widespread use of broad-spectrum antibiotics in newborns contributes to the emergence of resistant organisms, particularly among very low birth weight infants.
• Lumbar puncture decisions: There is ongoing debate about when to perform a lumbar puncture in infants being evaluated for EOS, balancing diagnostic yield against procedural risk and parental anxiety.
• Parental communication: The uncertainty of a “rule-out sepsis” workup can cause significant distress for families, requiring clear and empathetic explanation of the risk assessment process.

Likely Impact on Neonatal Care Protocols

The continued adoption of standardized risk calculators is expected to reduce the number of well-appearing infants who undergo full sepsis evaluations and prolonged antibiotic courses. Concurrently, the use of serial physical examinations and noninvasive biomarkers—such as C-reactive protein trends and procalcitonin—will likely become routine to guide decisions on when to safely discontinue therapy. This shift may also lower the incidence of complications from unnecessary line placement and antibiotic side effects. However, implementation remains uneven, with smaller or resource-limited units facing challenges in training, data collection, and access to rapid culture systems.

What to Watch Next

• Rapid molecular diagnostics: Multiplex PCR panels and other nucleic acid amplification tests are being studied for their ability to identify pathogens within hours rather than 24–48 hours, potentially transforming decision making.
• Machine learning models: Investigators are developing predictive algorithms that incorporate real-time vital signs and maternal data, though external validation and practical integration into electronic health records are still pending.
• Updated expert guidelines: Major professional bodies are expected to release revisions that further refine risk stratification criteria, particularly for late preterm infants and those born to mothers with suspected chorioamnionitis.
• Long-term outcomes research: Studies tracking neurodevelopment, allergy risk, and microbiome disruption in infants exposed to antibiotics for suspected EOS will inform future thresholds for treatment.